The present study revealed that the prognosis was significantly different between the HER2 heterogeneity group and the HER2 homogeneity group in patients with resectable primary adenocarcinoma of the stomach or gastro-esophageal junction. The gene discussed is ERBB2; the disease is adenocarcinoma.